Status: Acquired by Eli Lilly (2023)
Headquarters: Basel, Switzerland
Founded: 2015
Acquired by: Eli Lilly and Company
Acquisition date: 2023 ($60M upfront + milestones)
Website: asceneuron.com (redirects to Lilly neuroscience)
Asceneuron was a Swiss biotechnology company focused on developing small molecule OGA inhibitors for tauopathies. Founded in Basel, Switzerland, the company built a comprehensive OGA inhibitor pipeline including ASN90 and LY-3372689 (zaniglusemab), before being acquired by Eli Lilly in 2023 for $60M upfront plus development and commercial milestones.
Asceneuron's lead program, LY-3372689, was developed through:
- Discovery: Novel thiazolopyrimidine scaffold optimized for selectivity and CNS penetration
- Preclinical: Demonstrated robust efficacy in tauopathy mouse models
- Phase 1: Safety, tolerability, and target engagement (CSF O-GlcNAc) in healthy volunteers
- Phase 2 AD (MAGNOLIA): Early Alzheimer's disease — biomarker effects confirmed, did not meet primary cognitive endpoint
- Phase 2 PSP (LOTUS): First OGA inhibitor PSP trial — results expected Q4 2026
Prior to the Lilly acquisition, Asceneuron retained rights to ASN90:
- Scaffold: Thienopyrimidine-based OGA inhibitor
- Phase 1: Proof-of-concept in healthy volunteers
- Phase 2 (NCT05693982): Early Alzheimer's disease — novel scaffold may provide differentiation
The Lilly acquisition specifically excluded ASN90, which Asceneuron continued to develop independently.
Asceneuron's OGA inhibitor platform was built on:
- Structural biology: Deep understanding of OGA enzyme structure enabled rational inhibitor design
- Medicinal chemistry: Iterative optimization of selectivity, CNS penetration, and pharmacokinetics
- Biomarker strategy: Strong focus on CSF O-GlcNAc as pharmacodynamic marker
- Disease focus: Clear strategy targeting tauopathies with high unmet need (PSP, CBD, AD)
In 2023, Eli Lilly acquired Asceneuron for approximately $60M upfront with additional development and commercial milestones:
- Strategic rationale: Lilly sought to expand its neuroscience/tauopathy pipeline
- Complementary to remternetug: LY-3372689 + anti-tau antibody = dual tau strategy
- Swiss presence: Basel facility maintained as Lilly neuroscience research site
- Team retention: Key Asceneuron scientists joined Lilly's neuroscience division
Under Eli Lilly:
- LY-3372689 renamed zaniglusemab — integrated into Lilly's tau strategy
- MAGNOLIA trial (AD) completed 2024-2025 — biomarker effects but no cognitive benefit
- LOTUS trial (PSP) ongoing — results expected Q4 2026
- ASN90: Continued independent development by remaining Asceneuron entity